Provided by Tiger Trade Technology Pte. Ltd.

Alvotech

3.73
-0.1500-3.87%
Volume:640.18K
Turnover:2.41M
Market Cap:1.17B
PE:16.22
High:3.90
Open:3.86
Low:3.70
Close:3.88
52wk High:11.85
52wk Low:3.65
Shares:313.00M
Float Shares:116.17M
Volume Ratio:1.30
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2300
EPS(LYR):-0.8654
ROE:--
ROA:1.98%
PB:-6.60
PE(LYR):-4.31

Loading ...

Alvotech Announces Planned CEO Succession and Leadership Transition

THOMSON REUTERS
·
Jan 06

Press Release: Alvotech announces planned CEO succession and leadership transition

Dow Jones
·
Jan 06

BRIEF-Alvotech Secures Term Loan Facility Of USD 100 Million

Reuters
·
Jan 01

Alvotech Secures $100 Million Term Loan Led by GoldenTree Asset Management

Reuters
·
Jan 01

Alvotech Launches First Simponi Biosimilar in Europe

Reuters
·
Dec 24, 2025

Why Alvotech (ALVO) Is Down 8.5% After Securing a 2026 US Entry Window for AVT06

Simply Wall St.
·
Dec 24, 2025

Alvotech SA publishes update to financial calendar

Reuters
·
Dec 23, 2025

Alvotech Announces European Launch of First-in-Market Biosimilar to Simponi® (Golimumab) Globally by Partner Advanz Pharma

THOMSON REUTERS
·
Dec 22, 2025

Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

GlobeNewswire
·
Dec 22, 2025

Assessing Alvotech (NasdaqGM:ALVO)’s Valuation After FDA Setback and 2025 Guidance Cut

Simply Wall St.
·
Dec 22, 2025

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

GlobeNewswire
·
Dec 19, 2025

BRIEF-Alvotech and Teva Secure U.S. Settlement Date For AVT06

Reuters
·
Dec 19, 2025

Alvotech Sa - License Entry Date for Avt06 in U.S. Set for Q4 2026

THOMSON REUTERS
·
Dec 19, 2025

BRIEF-Alvotech SA Reaffirmed Full Year Outlook For 2025

Reuters
·
Dec 17, 2025

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Investors Digest Latest Economic Data

MT Newswires Live
·
Dec 17, 2025

Alvotech Sa - Reaffirmed Full Year Outlook for 2025

THOMSON REUTERS
·
Dec 17, 2025

Alvotech Sa - Anticipates 2026 Total Revenues in the Range of $650-$700 Million

THOMSON REUTERS
·
Dec 17, 2025

Alvotech Sa - 2026 Guidance Takes Into Account Impact of Any Further Delays in Obtaining Certain Marketing Approval From U.S. FDA

THOMSON REUTERS
·
Dec 17, 2025

Alvotech Sa: Co and U.S. Commercial Partner Reached Settlement and License Agreement With Regeneron Pharmaceuticals on Launch of Avt06 in US

THOMSON REUTERS
·
Dec 17, 2025

Alvotech Sa FY2026 Shr View $0.41, REV View $842.2 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
Dec 17, 2025